Arrhythmias & electrophysiology
Characteristics and Management of Patients With Cancer and Atrial Fibrillation: The BLITZ-AF Cancer Registry
Authors' conclusion
This study demonstrates that there is underuse of appropriate antithrombotic therapy for AF in cancer patients
Study context
- Population
- Patients with a recent cancer diagnosis and ECG-confirmed atrial fibrillation (AF)enrolled June 2019–September 2021
- Participants
- 1,514 patients
- Outcome
- Clinical characteristics and contemporary management, with focus on antithrombotic treatments
Methodological detailsmulticentre, BLITZ-AF Cancer Registry
- Multicentre
- BLITZ-AF Cancer Registry
Main finding
As reported in the abstract
Antithrombotic therapy before admission/cardiologist consultation vs at discharge/after cardiologic assessment
No antithrombotic therapy, before
16.6%
No antithrombotic therapy, after
7.7%
Antiplatelet agents and/or low-molecular-weight heparin, before
22.7%
Antiplatelet agents and/or low-molecular-weight heparin, after
16.6%
Observational data: associations, not effects.
Further findings
Baseline characteristics
- Mean age (years)
- 74 ± 9
- Age >75 years
- 47.5%
- Males
- 63.5%
- HF
- 20.9%
- CAD
- 18.1%
- Valvular heart disease
- 38.5%
- PAD
- 9.8%
- Previous thromboembolic events
- 13.9%
- Previous hemorrhagic events
- 10.4%
- CHA2DS2VASc score ≥4
- 41.5%
Most common cancer types
- Lung
- 14.9%
- Colorectal
- 14.1%
- Prostate
- 8.8%
- Non-Hodgkin lymphoma
- 8.1%
Original publication
Characteristics and Management of Patients With Cancer and Atrial Fibrillation: The BLITZ-AF Cancer Registry. JACC Adv. Published 24 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →